secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2025-05-02T23:59:59+00:00
Accession:  0001723128-25-000018
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal Q1 revenue $695M (+5% YoY), net income $12M vs loss, adj EPS $0.21 (+50%), reaffirms guidance
--------------------------------------------------------------------------------

- Net revenue $695M, up 5% YoY; GAAP net income $12M vs $92M loss in Q1 2024; diluted EPS $0.04 vs ($0.30).
- Adjusted EBITDA $170M (+12% YoY); adjusted diluted EPS $0.21 (+50% from $0.14).
- Affordable Medicines +6%, Specialty +3%, AvKARE +6%; CREXONT and injectable momentum cited.
- Company reaffirms 2025 full-year guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312825000018/0001723128-25-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312825000018/amrx-20250502.htm
  HTML page:      https://secwatch.observer/filing/0001723128-25-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer